Trial Profile

An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Carcinoid tumour; Colorectal cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

22 Nov 2022 Status changed from active, no longer recruiting to discontinued.
26 May 2022 Planned primary completion date changed from 1 May 2022 to 1 May 2023.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com